RAZADYNE ORAL SOLUTION Rx
Generic Name and Formulations:
Galantamine (as HBr) 4mg/mL.
Janssen Pharmaceuticals, Inc.
Indications for RAZADYNE ORAL SOLUTION:
Mild to moderate Alzheimer's dementia.
Give with AM & PM meals. Initially 4mg twice daily; if well-tolerated, increase to maintenance dose 8mg twice daily (16mg/day) after minimum of 4 weeks; may attempt further increase to 12mg twice daily (24mg/day) after minimum of 4 weeks. Re-titrate if interrupted for >3 days. Moderate hepatic or renal impairment (CrCl 9–59mL/min): usual max 16mg/day.
Discontinue at the first sign of skin rash, unless not drug-related; consider alternative therapy if serious skin reactions occur. Conduction disorders (eg, bradycardia, AV block). History of ulcer disease. Bladder outflow obstruction. Asthma. COPD. Seizures. Monitor for active or occult GI bleed, respiratory or neurological effects, and patient's weight. Maintain adequate hydration. Severe hepatic or renal impairment (CrCl <9mL/min): not recommended. Pregnancy (Cat.C). Nursing mothers.
Reversible acetylcholinesterase inhibitor (benzazepine deriv).
Potentiates neuromuscular blockers (eg, succinylcholine), cholinesterase inhibitors, cholinergic agonists (eg, bethanechol). Antagonizes anticholinergics. Caution with drugs that slow heart rate. May be potentiated by ketoconazole, cimetidine, paroxetine, fluoxetine, erythromycin, possibly others that affect CYP2D6 or CYP3A4. Monitor for GI bleed with NSAIDs.
Nausea, vomiting, diarrhea, dizziness, headache, decreased appetite, anorexia, weight loss, syncope, bradycardia, heart block, seizures; serious skin reactions (eg, Stevens-Johnson syndrome).
This product was formerly named Reminyl.
Tabs—60; Soln—100mL (w. cal. pipette); ER caps—30
Neurology Advisor Articles
- Deep Brain Stimulation Improves Parkinson Disease in Older Adults
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis